Clinical trials: Sitagliptin, completed
Type 2 Diabetes Mellitus, Cardiovascular Disease
Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)
There are recent advances in therapies for the treatment of Type 2 Diabetes Mellitus (T2DM) which include the GLP1 analogues and the DPP IV inhibitors.
- Trial name
- LYDIA (NCT02043054)
- Testing
- Liraglutide, Sitagliptin
- Where
- United Kingdom
- Volunteers
- 90 people
- Sponsor
- University of Leicester
Uncontrolled Type 2 Diabetes Mellitus
Sitagliptin vs. Pioglitazone as add-on Treatments in Patients With Type 2 Diabetes Uncontrolled on the Full-dose Metformin Plus Sulfonylurea
This study has been designed to investigate the comparative effects of sitagliptin vs. pioglitazone as add-on treatments in patients with type 2 diabetes who were uncontrolled on the full-dose of metformin and sulfonylurea
- Trial name
- NCT03125694
- Testing
- Sitagliptin 100mg, Pioglitazone 30 mg
- Where
- Iran
- Volunteers
- 250 people
- Sponsor
- Tehran University of Medical Sciences
Type 2 Diabetes
A Study to Demonstrate the Bioequivalence of Sitagliptin/Metformin Combination Tablets and Concomitant Administration of Sitagliptin and Metformin as Individual Tablets (0431A-048)
A two-part study to demonstrate the bioequivalence of a single dose of the Final Market Image (FMI) of sitagliptin /metformin (50/500 and 50/1000 mg) Fixed-Dose Combination (FDC) tablet and co-administration of a single dose of…
- Trial name
- NCT00961857
- Testing
- sitagliptin phosphate (+) metformin hydrochloride, Comparator: metformin 500 mg, Comparator: sitagliptin
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin
The objectives of the study is to evaluate the efficacy and safety of DS-8500a compared with placebo in patients with type 2 diabetes mellitus (T2DM) receiving sitagliptin.
- Trial name
- NCT02685345
- Testing
- DS-8500a 25 mg, DS-8500a 75 mg
- Where
- Japan
- Volunteers
- 85 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Type 2 Diabetes
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Sitagliptin in Adolescents (0431-081)
This study will assess the safety, tolerability and pharmacokinetics of sitagliptin in 10 to 17 year old diabetic patients.
- Trial name
- NCT00730275
- Testing
- Sitagliptin phosphate
- Volunteers
- 35 people
- Sponsor
- Merck Sharp & Dohme LLC
Glucose Intolerance
Sitagliptin in Renal Transplant Recipients
The major cause of premature death in renal transplant recipients is cardiovascular disease. Sitagliptin stimulates insulin secretion and inhibits glucagon release, two central mechanisms in PTDM by interaction with a hormone…
- Trial name
- NCT00740363
- Testing
- sitagliptin
- Where
- Norway
- Volunteers
- 25 people
- Sponsor
- University of Oslo School of Pharmacy
Diabetes Mellitus, Non-Insulin-Dependent
Addition Of Januvia (Sitagliptin) Improves Glycemic Control In Patients Inadequately Controlled By Metformin (MK0431-078)
To compare the efficacy of three strategies of lifestyle changes associated with Januvia (sitagliptin) 100 mg/day in patients with Type 2 Diabetes Mellitus (T2DM) inadequately controlled by metformin (hemoglobin A1c [HbA1c]…
- Trial name
- NCT00545584
- Testing
- sitagliptin phosphate, Comparator: Diet, Comparator: Physical Activity
- Volunteers
- 1,512 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Sitagliptin and Kinetics of Triglyceride-rich Lipoproteins Apolipoprotein B48 and B100 in Patients With Type 2 Diabetes
Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-IV), and has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes mainly through incretin hormone-mediated…
- Trial name
- JANUB48 (NCT01334229)
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 22 people
- Sponsor
- Laval University
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin
This trial is conducted in Asia, Europe and North America. The aim of the trial is to investigate the efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes not achieving adequate…
- Trial name
- LIRA-SWITCH™ (NCT01907854)
- Testing
- liraglutide, sitagliptin
- Where
- 106 sites in United States, Canada and 5 more
- Volunteers
- 407 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Evaluation of the Effect of Dapagliflozin in Combination With Metformin on Body Weight in Subjects With Type 2 Diabetes
This study is being carried out to see if dapagliflozin in addition to metformin decreases body weight and if so, how it compares with metformin alone.
- Trial name
- NCT00855166
- Testing
- Dapagliflozin, Metformin, Sitagliptin
- Where
- 21 sites in Bulgaria, Czechia and 3 more
- Volunteers
- 182 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)
This study will examine the safety and efficacy of the addition of sitagliptin (MK-0431) compared to placebo in patients with type 2 diabetes mellitus with inadequate glycemic control who are taking pioglitazone and metformin.
- Trial name
- NCT00885352
- Testing
- Sitagliptin, Pioglitazone, Metformin
- Volunteers
- 313 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus, Hospitalization
Dipeptidyl Peptidase-4 Inhibitor (Sitagliptin) Therapy in the Inpatients With Type 2 Diabetes
The study is a multicenter, prospective, open-label, randomized pilot study to investigate the safety and efficacy of sitagliptin (Januvia) for the inpatient management of type 2 diabetes (T2D) in general medicine and surgery…
- Conditions
- Type 2 Diabetes Mellitus, Hospitalization, Hyperglycemia
- Trial name
- NCT01378117
- Testing
- Sitagliptin, glargine, lispro
- Where
- 2 sites in United States
- Volunteers
- 90 people
- Sponsor
- Emory University
Newly Diagnosed Type 2 Diabetes
Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs
Epidemiologic, social and economic burdens of type 2 diabetes mellitus (T2DM) keep rising worldwide. Implementation of T2DM preventive trategies is lagging behind.
- Trial name
- MIRACLE (NCT04271189)
- Testing
- Metformin-Sitagliptin-Empaglifozin-Pioglitazone, Standard of care
- Where
- Italy
- Volunteers
- 108 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Parma
Lewy Body Dementia, Parkinson Disease
Anti-Diabetic Medications to Fight PD and LBD
The purpose of this study is to test the hypothesis that DPP4 inhibitors and SGLT2 inhibitors are well tolerated and have beneficial neurological effects, specifically for Parkinson's disease and Lewy body dementia.
- Trial name
- NCT06263673
- Testing
- Sitagliptin, Dapagliflozin
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mayo Clinic
Diabetes
Predictive Parameters for Efficacy of Sitagliptin and Metformin Combination
It is well established that inhibition of dipeptidyl peptidase (DPP)-IV reduces glucose levels in both fasting and postprandial states and preserves pancreatic beta cell function in patients with type 2 diabetes.
- Trial name
- COSMETIC (NCT00969566)
- Testing
- sitagliptin, metformin
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Seoul National University Bundang Hospital
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetics of Single and Multiple Doses of Orally Administered GSK1292263 to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics
The purpose of this study is to see if GSK1292263 is safe and well-tolerated when administered to type 2 diabetics, and to get preliminary information about whether it may be effective in the treatment of type 2 diabetes.
- Trial name
- NCT01119846
- Testing
- GSK1292263, Sitagliptin
- Where
- 7 sites in United States
- Volunteers
- 100 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
A Study Based on Data From German Sick Funds That Looks at the Costs of Treatment of Type-2 Diabetic Patients With Empagliflozin vs. DPP-4 Inhibitors vs. GLP-1 Receptor Agonists
Empagliflozin vs. Dipeptidyl Peptidase 4 (DPP-4) Inhibitors and Glucagon-like Peptide-1 Receptor Agonists (GLP-1-RA) Cost of Care Study: a German claims data analysis
- Trial name
- NCT04295005
- Testing
- Empagliflozin, DPP-4i, GLP-1-RA
- Where
- Germany
- Volunteers
- 24,500 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)
This is a study to assess the safety and efficacy of the addition of ipragliflozin to sitagliptin in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and…
- Trial name
- NCT02564211
- Testing
- Ipragliflozin, Sitagliptin
- Volunteers
- 77 people
- Sponsor
- Merck Sharp & Dohme LLC
Type II Diabetes
Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763
This study is a three part study to assess the safety and efficacy of LEZ763 on normal healthy volunteers and patients with Type 2 Diabetes.
- Trial name
- NCT01619332
- Testing
- Sitagliptin, LEZ763
- Where
- 6 sites in United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Diabetes Mellitus, Type 2
Emulating the PIONEER6 Diabetes Trial Using Healthcare Claims
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials.
- Trial name
- NCT06659679
- Testing
- New use of oral semaglutide, New initiation of sitagliptin
- Where
- United States
- Volunteers
- 26,126 people
- Sponsor
- Brigham and Women's Hospital